News
PHVS
30.71
-0.05%
-0.02
Pharvaris Highlights New Deucrictibant Data at EAACI 2026, Says HAE Treatment Data Support On-Demand and Preventive Use
Benzinga · 3h ago
Pharvaris says Phase 3 RAPIDe-3 trial shows oral deucrictibant cuts median HAE symptom relief time to 1.28 hours
PUBT · 3h ago
Weekly Report: what happened at PHVS last week (0608-0612)?
Weekly Report · 5h ago
Buy Rating Reiterated on Pharvaris with Unchanged $52 Price Target Ahead of Key Phase 3 Deucrictibant XR Readout
TipRanks · 3d ago
Pharvaris publishes patient-reported outcomes presentation on clinical evidence in HAE trials
PUBT · 3d ago
Pharvaris Sets June 26, 2026 AGM as Late-Stage Angioedema Programs Advance
TipRanks · 4d ago
Pharvaris Announces Annual General Meeting of Shareholders
Barchart · 4d ago
Why Pharvaris (PHVS) Is Up 8.6% After Expanding Deucrictibant HAE Data And Regulatory Plans
Simply Wall St · 6d ago
Pharvaris Executive Makes Notable Move in Latest Insider Stock Sale
TipRanks · 6d ago
Weekly Report: what happened at PHVS last week (0601-0605)?
Weekly Report · 06/08 09:03
A Look At Pharvaris (PHVS) Valuation As Deucrictibant Data Advances Toward Key EAACI 2026 Catalyst
Simply Wall St · 06/07 13:28
Pharvaris management to meet with Oppenheimer
TipRanks · 06/03 19:50
Most and least shorted mid- to mega-cap healthcare stocks at the end of May
Seeking Alpha · 06/03 13:35
Weekly Report: what happened at PHVS last week (0525-0529)?
Weekly Report · 06/01 09:03
The Bull Case For Pharvaris (PHVS) Could Change Following New Deucrictibant Phase 3 Data Disclosures
Simply Wall St · 05/31 13:12
Pharvaris management to meet with Oppenheimer
TipRanks · 05/29 20:40
Pharvaris to present Phase 3 RAPIDe-3 end-of-progression data for oral deucrictibant in hereditary angioedema at EAACI 2026
PUBT · 05/29 10:51
Pharvaris Maintained at Buy as Analyst Reaffirms $52 Price Target on Deucrictibant Late-Stage Strength and M&A Optionality
TipRanks · 05/28 00:43
Top Pharvaris Insiders Quietly Cash Out in Significant Share Sales
TipRanks · 05/27 02:12
Pharvaris Principal Accounting Officer Anna Nijdam disposes of common shares worth $224,207.69
PUBT · 05/26 21:46
More
Webull provides a variety of real-time PHVS stock news. You can receive the latest news about Pharvaris N.V. through multiple platforms. This information may help you make smarter investment decisions.
About PHVS
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.